Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolterodine

C J Hills1, S A Winter, J A Balfour

  • 1Adis International Limited, Chester, England and Auckland, New Zealand.

Drugs
|June 9, 1998
PubMed
Summary
This summary is machine-generated.

Tolterodine effectively treats overactive bladder by reducing urination frequency and incontinence. This muscarinic antagonist offers comparable efficacy to oxybutynin but with a significantly lower incidence of dry mouth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Topical eflornithine.

American journal of clinical dermatology·2001
Same author

Telithromycin.

Drugs·2001
Same author

Bendamustine.

Drugs·2001
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Overactive bladder (OAB) is a condition characterized by urinary urgency, frequency, and incontinence.
  • Tolterodine is a recently introduced competitive muscarinic receptor antagonist for OAB treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of tolterodine in patients with overactive bladder.
  • To compare tolterodine's effects on bladder function and salivation with oxybutynin.

Main Methods:

  • Functional selectivity assessment in vivo.
  • In vitro assessment of potency in inhibiting bladder contraction and salivation.
  • Clinical trials comparing tolterodine and oxybutynin in OAB patients.

Main Results:

  • Tolterodine demonstrates functional selectivity for the bladder over salivary glands.

Related Experiment Videos

  • It is equipotent to oxybutynin in inhibiting bladder contractions but less potent in inhibiting salivation.
  • Tolterodine significantly reduces OAB symptoms (micturition frequency, incontinence episodes) with rapid onset and sustained efficacy.
  • Comparative trials show equivalent efficacy to oxybutynin but significantly better tolerability, especially regarding dry mouth.

    • Conclusions:

    • Tolterodine is an effective and well-tolerated treatment for overactive bladder.
    • Its favorable side effect profile, particularly reduced dry mouth, makes it a valuable alternative to oxybutynin.